SCOPUS 정보 검색 플랫폼

Volumn 86, Issue 5, 2002, Pages 692-697

Sequential or alternating administration of docetaxel (Taxotere®) combined with FEC in metastatic breast cancer: A randomised phase II trial

(8) Spielmann, M a Tubiana Hulin, M b Namer, M c Mansouri, H a Bougnoux, P d Tubiana Mathieu, N e Lotz, V f Eymard, J C g

a INSTITUT GUSTAVE ROUSSY (France)

b CENTRE RENÉ HUGUENIN (France)

c CENTRE ANTOINE LACASSAGNE (France)

d CHU BRETONNEAU (France)

e DUPUYTREN UNIVERSITY HOSPITAL (France)

f SANOFI (France)

g INSTITUT JEAN GODINOT (France)

Author keywords

Alternating therapy; Docetaxel; FEC; Metastatic breast cancer; Sequential therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME;

EID: 0037017874 PISSN: 00070920 EISSN: None Source Type: Journal
DOI: 10.1038/sj.bjc.6600165 Document Type: Article

Times cited : (24)

References (26)

1
- 0027471578
- Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens
- (1993) Br J Cancer , vol.67 , pp. 801-805
- A'Hern, R.P.¹ Smith, I.E.² Ebbs, S.³

2
- 0028813358
- Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results
- (1995) JAMA , vol.273 , pp. 542-547
- Bonadonna, G.¹ Zambetti, M.² Valagussa, P.³

3
- 0032829692
- Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: The French compassionate use programme experience
- (1999) Eur J Cancer , vol.35 , pp. 1431-1439
- Bonneterre, J.¹ Spielmann, M.² Guastalla, J.-P.³ Marry, M.⁴ Viens, P.⁵ Chollet, P.⁶ Roché, H.⁷ Fumoleau, P.⁸ Mauriac, L.⁹ Bourgeois, H.¹⁰ Namer, M.¹¹ Bergerat, J.P.¹² Misset, J.-L.¹³ Trandafir, L.¹⁴ Mahjoubi, M.¹⁵

4
- 0034060505
- Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab
- (2000) Semin Oncol , vol.27 , pp. 19-23
- Burris, H.A.¹

5
- 0033404724
- Metastatic breast cancer patients failing first-line, anthracycline-containing chemotherapy: Is further therapy of benefit?
- (1999) Anticancer Res , vol.19 , pp. 3429-3432
- Campora, E.¹ Gardin, G.² Gasco, M.³ Rosso, R.⁴ Santi, L.⁵

6
- 0032787785
- Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
- (1999) J Clin Oncol , vol.17 , pp. 2341-2354
- Chan, S.¹ Friedrichs, K.² Noel, D.³ Pintér, T.⁴ Van Belle, S.⁵ Vorobiof, D.⁶ Duarte, R.⁷ Gil Gil, M.⁸ Bodrogi, I.⁹ Murray, E.¹⁰ Yelle, L.¹¹ Von Minckwitz, G.¹² Korec, S.¹³ Simmonds, P.¹⁴ Buzzi, F.¹⁵ Mancha, R.G.¹⁶ Richardson, G.¹⁷ Walpole, E.¹⁸ Ronzoni, M.¹⁹ Murawsky, M.²⁰ more..

7
- 0023145358
- Survival from first recurrence: Relative importance of prognostic factors in 1015 breast cancer patients
- (1987) J Clin Oncol , vol.5 , pp. 55-61
- Clark, G.M.¹ Sledge, G.W.² Osborne, C.K.³ McGuire, W.L.⁴

8
- 0022504529
- Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy
- (1986) Cancer Res , vol.46 , pp. 3876-3885
- Day, R.S.¹

9
- 0034013781
- A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer
- (2000) Ann Oncol , vol.11 , pp. 169-175
- Di Leo, A.¹ Crown, J.² Nogaret, J.M.³ Duffy, K.⁴ Bartholomeus, S.⁵ Dolci, S.⁶ Rowan, S.⁷ O'Higgins, N.⁸ Paesmans, M.⁹ Larimont, D.¹⁰ Riva, A.¹¹ Piccart, M.J.¹²

10
- 0031816746
- Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group
- (1998) Cancer Prev Con , vol.2 , pp. 140-146
- Findlay, B.P.¹ Walker-Dilks, C.²

11
- 0020108590
- One-sample multiple testing procedure for phase II clinical trials
- (1982) Biometrics , vol.38 , pp. 143-151
- Fleming, T.R.¹

12
- 0031759089
- Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31, 510 women
- (1998) J Clin Oncol , vol.16 , pp. 3439-3460
- Fossati, R.¹ Confalonieri, C.² Torri, V.³ Ghislandi, E.⁴ Penna, A.⁵ Pistotti, V.⁶ Tinazzi, A.⁷ Liberati, A.⁸

13
- 0023934166
- A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin
- (1988) J Clin Oncol , vol.6 , pp. 679-688

14
- 0026062132
- A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients
- (1991) J Clin Oncol , vol.9 , pp. 305-312

15
- 0031457575
- Efficacy and safety of docetaxel in clinical trials
- (1997) Am J Health Syst Pharm , vol.54 , pp. S19-S24
- Fumoleau, P.¹

16
- 0032721964
- Cardiotoxicity of epirubicin/paclitaxel-containing regimens: Role of cardiac risk factors
- (1999) J Clin Oncol , vol.17 , pp. 3596-3602
- Gennari, A.¹ Salvadori, B.² Donati, S.³ Bengala, C.⁴ Orlandini, C.⁵ Danesi, R.⁶ Del Tacca, M.⁷ Bruzzi, P.⁸ Conte, P.F.⁹

17
- 0019952884
- Rationale for the use of alternating non-cross-resistant chemotherapy
- (1982) Cancer Treat Rep , vol.66 , pp. 439-449
- Goldie, J.H.¹ Coldman, A.J.² Gudauskas, G.A.³

18
- 0001025201
- Chemotherapy for metastatic disease
- Harris JR, Hellman S, Henderson IC, et al (eds), Philadelphia, PA: Lippincott
- Breast Diseases 2nd edn , pp. 604-665
- Henderson, I.C.¹

19
- 0032919709
- Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high risk breast cancer: Feasibility and efficacy
- (1999) J Clin Oncol , vol.17 , pp. 93-100
- Hudis, C.¹ Seidman, A.² Baselga, J.³ Raptis, G.⁴ Lebwohl, D.⁵ Gilewski, T.⁶ Moynahan, M.⁷ Sklarin, N.⁸ Fennelly, D.⁹ Crown, J.P.A.¹⁰ Surbone, A.¹¹ Uhlenhopp, M.¹² Riedel, E.¹³ Yao, T.J.¹⁴ Norton, L.¹⁵

20
- 0023924386
- Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide vs fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial
- (1988) J Clin Oncol , vol.6 , pp. 976-982

21
- 0028763580
- ABC of breast diseases. Metastatic breast cancer
- (1994) Br Med J , vol.309 , pp. 1501-1504
- Leonard, R.C.F.¹ Rodger, A.² Dixon, J.M.³

22
- 0032949449
- Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
- (1999) J Clin Oncol , vol.17 , pp. 1413-1424
- Nabholtz, J.-M.¹ Senn, H.J.² Bezwoda, W.R.³ Melnychuk, D.⁴ Deschênes, L.⁵ Douma, J.⁶ Vandenberg, T.A.⁷ Rapoport, B.⁸ Rosso, R.⁹ Trillet-Lenoir, V.¹⁰

23
- 0032753724
- Epirubicin: A review of its efficacy and adjuvant therapy and in the treatment of metastatic disease in breast cancer
- (1999) Drugs Aging , vol.15 , pp. 389-416
- Ormrod, D.¹ Holm, K.² Goa, K.³ Spencer, C.⁴

24
- 0031734394
- Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer
- (1998) J Clin Oncol , vol.16 , pp. 3502-3508
- Ryberg, M.¹ Nielsen, D.² Skovsgaard, T.³ Hansen, J.⁴ Jensen, B.V.⁵ Dombernowsky, P.⁶

25
- 17344390083
- Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group
- (1999) Eur J Cancer , vol.35 , pp. 1194-1201
- Sjöström, J.¹ Blomqvist, C.² Mouridsen, H.³ Pluzanska, A.⁴ Ottosson-Lonn, S.⁵ Bengtsson, N.O.⁶ Ostenstad, B.⁷ Mjaaland, I.⁸ Palm-Sjovall, M.⁹ Wist, E.¹⁰ Valvere, V.¹¹ Anderson, H.¹² Bergh, J.¹³

26
- 0029563137
- Docetaxel (Taxotere): An effective agent in the management of second-line breast cancer
- (1995) Semin Oncol , vol.22 , pp. 22-28
- Van Oosterom, A.T.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.